NASDAQ OMX

LivaNova Reports First Quarter 2016 Results

4.5.2016 13:00 | NASDAQ OMX

Del

LONDON, 2016-05-04 13:00 CEST (GLOBE NEWSWIRE) --

LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the first quarter ended March 31, 2016. 

For the first quarter of 2016, worldwide sales were $287 million, an increase of 3.0 percent on a constant currency1 basis as compared to the previous year.  On a reported basis, sales increased by 1.2 percent for this period.  First quarter 2016 adjusted2 diluted earnings per share were $0.54.  On a U.S. Generally Accepted Accounting Principles (GAAP) basis, first quarter 2016 diluted loss per share were ($0.83).

“LivaNova has started the year with solid results in line with our expectations, driven primarily by continued momentum in our Neuromodulation business with AspireSR®,” said André-Michel Ballester, Chief Executive Officer.  “We made significant progress on the regulatory front with approvals during the quarter of both our Perceval sutureless valve in the U.S. and our KORA 250 fully MRI compatible pacemaker in Japan.  Looking forward, we believe our regulatory progress as well as our keen focus on execution positions us well to deliver on our synergy targets and financial commitments for 2016.  We look forward to continuing to deliver high-quality devices that meet the needs of our customers and patients around the world.”

___________

1 Constant currency growth measures the change in sales between the current and prior year periods using average exchange rates in effect during the applicable prior year period.

Adjusted measures exclude certain specified items as described later in this press release and the attached schedules.  Adjusted measures are based on selected non-GAAP operating results highlights in our 2015 Annual and Fourth Quarter Financial Results published on February 24, 2016.

First-Quarter 2016

The following table highlights selected financial results3 for the first quarter of 2016 compared to the same period in 2015:

 

  Three Months Ended 
March 31,
% Change Constant 
Currency 
% Change
In $ millions   2016     2015  
Cardiac Surgery $ 143.4   $ 142.2     0.9 %   3.2 %
Cardiopulmonary $ 110.9   $ 107.5     3.1 %   5.5 %
Heart Valves $ 32.5   $ 34.7     (6.2 %)   (3.7 %)
CRM4 $ 61.7   $ 70.4     (12.3 %)   (10.7 %)
Neuromodulation $ 81.4   $ 70.1     16.0 %   16.4 %
Other $ 0.4   $ 0.7     N/A   N/A
Total Net Sales $ 287.0   $ 283.4     1.2 %   3.0 %

 

  • Numbers may not add due to rounding.

For discussion purposes, all sales growth rates below reflect comparable, constant currency growth. 

Three months ended March 31, 2016
For the three primary Business Units, sales were as follows:

Cardiac Surgery 
Cardiac Surgery sales, which include cardiopulmonary products and heart valves, were $143 million, representing a 3.2 percent increase versus the comparable period in 2015. 

Sales in cardiopulmonary products were $111 million, an increase of 5.5 percent compared to the first three months of 2015.  This was due to high demand for our heart lung machines, particularly in the U.S., and strong demand for oxygenators in emerging markets as well as in Japan and Australia.      

Heart valve sales, including tissue and mechanical heart valves, were $33 million, a decrease of 3.7 percent compared to the same period the previous year. Results were driven by strength in Perceval in Europe, which was more than offset by weakness in mechanical valves in China and traditional tissue valves globally.  Perceval in Europe has continued to gain momentum across the region, and physician response of Perceval in the U.S. has been positive since the launch early in the quarter. 

___________

3 See the discussion of “Financial Alignment, Combined Sales & Operating Results, Business Unit Structure and Constant Currency” below.  The sales results presented are unaudited.

4 Cardiac Rhythm Management.

Cardiac Rhythm Management 
CRM sales for the period totaled $62 million, a decrease of 10.7 percent, primarily a result of timing as we transitioned customers from KORA 100 to our recent MRI compatible device KORA 250 in Japan.  This was partially offset by strong performance of our newest high-voltage device Platinium, which was launched last November in Europe and Japan.

Neuromodulation
Neuromodulation sales were $81 million in the first quarter, an increase of 16.4 percent, driven primarily by continued adoption of our newest VNS therapy device AspireSR in the U.S. and new patient growth.

Financial Performance
Adjusted income from operationsfor the first quarter of 2016 was $44 million, an increase of 17.9 percent as compared to first quarter of 2015.  On a U.S. GAAP basis, first quarter 2016 loss from operations was $36.1 million.  “Adjusted income from operations for the quarter reflects sound cost controls and early results from the synergy targets outlined on prior calls.  Further cost reduction will result from the CRM restructuring announced on March 10, 2016. Gross margin also continues to be in line with our projections”, said Vivid Sehgal, Chief Financial Officer.  “With the expectation of higher sales in the second half of 2016, continued reduction of debt and ongoing tax planning activities, our focus on leveraging the income statement should be reflected in the full year’s results”.

2016 Projections
The Company today reiterated its guidance for full year 2016. 

For full year 2016, the Company expects revenue growth on a constant-currency basis in the range of 3 to 5 percent.  This includes growth in Cardiac Surgery of 3 to 5 percent, growth in Neuromodulation of 9 to 11 percent and growth in CRM of 1 to 2 percent. 

The Company continues to expect adjusted gross profit in the range of 64 to 65 percent of net sales, R&D expenses between 11 and 12 percent of net sales, and adjusted income from operations in the range of $205 to $230 million.  Adjusted EBITDA is expected to be in the range of $235 to $260 million.

Finance costs and the Company’s share of losses from minority investments are expected to be approximately $20 to $25 million, and the adjusted effective tax rate is expected to be between 24 and 26 percent.  The Company continues to project adjusted diluted earnings per share (EPS) in the range of $2.95 to $3.15.  This is based on a share count of approximately 50 million shares on a fully diluted basis. 

___________

5 Adjusted measures exclude certain specified items as described later in this press release and the attached schedules.  Adjusted measures are based on selected non-GAAP operating results highlights in our 2015 Annual and Fourth Quarter Financial Results published on February 24, 2016.

Webcast and Conference Call Instructions
The conference call will be available to interested parties through a live audio webcast commencing at 8:00 AM Central time (9:00 AM Eastern Time, 2:00 pm UK Time) and accessible through the Investor Relations section of the LivaNova corporate website at www.livanova.com.  To listen to the conference call live by telephone, dial 877-809-8594 (if dialing from within the U.S.) or 440-996-5677 (if dialing from outside the U.S.).  The conference ID is 73271166.  Please click here for a list of available local international numbers for the call.

Within 24 hours of the webcast, a replay will be available under the "Events & Presentations" section of the Investor Relations portion of the LivaNova website, where it will be archived and accessible for approximately 12 months.

About LivaNova

LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems.  The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm Management, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and is admitted to the standard listing segment of the Official List of the UK’s Financial Conduct Authority and to trading on the London Stock Exchange (LSE) under the ticker symbol “LIVN”.

Financial Alignment, Combined Sales & Operating Results, Business Unit Structure and Constant Currency

Cyberonics, the predecessor company to LivaNova, previously reported on a 52/53 week fiscal year calendar ending in April.  With the formal change in the fiscal calendar to a fiscal year ended December 31, the historical Neuromodulation business unit sales have been aligned to correspond as closely as possible to calendar quarters.

Although LivaNova was a shell company with no business operations until the closing date of the merger on October 19, 2015, the sales results disclosed for periods up to and beyond that date are being provided on a combined basis, a non-GAAP formulation that combines the results of legacy Sorin and Cyberonics for the periods completed prior to the merger and periods that include results both before and after the closing of the merger.  The Company believes that presenting the results of Sorin and Cyberonics in such a manner offers a meaningful representation to investors of the combined company’s sales for these periods.

Non-GAAP operating results, unaudited, have been included for each of the quarters ended March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015 and for the year ended December 31, 2015.  These results have been prepared by management and adjusted for non-GAAP items as if the merger had occurred on January 1, 2015 but should not be considered as an alternative to Proforma Income Statements to be provided in accordance with SEC filings.  Certain adjustments to legacy Sorin operating results have occurred in order to present the results in US dollars and to align these results as closely as possible to the presentation of LivaNova financial results.  Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies.  Management believes that the presentation of these results provides a meaningful representation of the combined company’s operating results for the periods presented.

The sales and operating results for legacy Cyberonics for the quarters ended March 31, June 30 and September 30 were aligned to provide comparative information. The actual periods ended on March 27, June 26 and September 25 respectively.

LivaNova (as the successor to Sorin and Cyberonics on a combined basis) operates under a Business Unit structure with Cardiac Surgery, CRM and Neuromodulation accounting for substantially all of the sales during the periods referred to herein.  The combined company also operates a New Ventures group, dedicated to developing new technologies, particularly in the areas of heart failure, sleep apnea and percutaneous mitral valve. 

Unless otherwise noted, all sales growth rates in this release reflect comparable, constant currency growth.  Constant currency growth measures the change in sales between current and prior year periods using average exchange rates in effect during the applicable prior year period.  Management believes that referring to comparable, constant currency growth is a more useful way to evaluate the sales performance of the newly formed LivaNova and its business units, and to compare the sales performance of current periods to prior periods on a consistent basis.  A reconciliation of this information is attached to this business update.

Use of Non-GAAP Financial Measures

In this press release, management has disclosed financial measurements that present financial information not necessarily in accordance with Generally Accepted Accounting Principles (GAAP). Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly-titled measures used by other companies.  These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP.

Unless otherwise noted, all sales growth rates in this release reflect comparable, constant currency growth. Management believes that referring to comparable, constant currency growth is the most useful way to evaluate the sales performance of LivaNova and to compare the sales performance of current periods to prior periods on a consistent basis. Constant currency growth, a non-GAAP financial measure, measures the change in sales between current and prior year periods using average exchange rates in effect during the applicable prior year period.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended.  Forward-looking statements are not historical facts but are based on certain assumptions of management and describe the Company’s future plans, strategies and expectations.  Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Forward-looking statements contained in this press release are based on information presently available to LivaNova and assumptions that the Company believes to be reasonable, but are inherently uncertain.  As a result, our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control.  Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning developing novel opportunities in neuromodulation, heart failure, sleep apnea and percutaneous mitral valve, creating new innovative solutions that benefit patients, healthcare professionals, and healthcare systems, and building significant shareholder value.  Important factors that may cause actual results to differ include, but are not limited to:  (i) risks that the legacy businesses of Cyberonics, Inc. and Sorin S.p.A. (together, the “combined companies”) will not be integrated successfully or that the combined companies will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer to realize than expected; (ii) the inability of LivaNova to meet expectations regarding the timing, completion and accounting of tax treatments; (iii) risks relating to unanticipated costs of integration, including operating costs, customer loss or business disruption being greater than expected; (iv) our organizational and governance structure; (v) reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; (vi) unanticipated changes relating to competitive factors in the industries in which LivaNova operates; (vii) the ability to hire and retain key personnel; (viii) the ability to attract new customers and retain existing customers in the manner anticipated; (ix) the reliance on and integration of information technology systems; (x) changes in legislation or governmental regulations affecting LivaNova; (xi) international, national or local economic, social or political conditions that could adversely affect LivaNova, its partners or its customers; (xii) conditions in the credit markets; (xiii) business and other financial risks inherent to the industries in which LivaNova operates; (xiv) risks associated with assumptions made in connection with critical accounting estimates and legal proceedings; (xv) LivaNova’s international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; (xvi) and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs.  The foregoing list of factors is not exhaustive.  You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-4 and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova. LivaNova does not give any assurance (1) that LivaNova will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results.

All information in this press release is as of the date of its release.  The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.  If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.  We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release.

For more information, please visit www.livanova.com, or contact:

Investor Relations and Media

Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com

LIVANOVA PLC
QUARTERLY SALES TREND BY BUSINESS UNIT 
U.S. dollar in millions, CONSTANT CURRENCY

 

      1Q15       2Q15       3Q15       4Q15       FY15       1Q16       1Q16 vs. 1Q15  
Net sales                                                        
                                                         
Cardio Pulmonary   $ 107.5     $ 125.9     $ 113.0     $ 130.0     $ 476.4     $ 113.4         5.5 %  
Heart Valves     34.7       36.4       34.2       34.9       140.2       33.4         (3.7 %)  
                                                         
Cardiac Surgery Total     142.2       162.3       147.2       164.9       616.6       146.8         3.2 %  
CRM     70.4       75.6       53.9       60.7       260.5       62.9         (10.7 %)  
Neuromodulation     70.1       78.4       84.3       91.5       324.3       81.6         16.4 %  
                                                         
Other     0.7       0.7       0.8       0.9       3.2       0.5         NM    
                                                         
Total   $ 283.4     $ 317.1     $ 286.1     $ 318.0     $ 1,204.6     $ 291.8         3.0 %  
                                                             

 

QUARTERLY SALES TREND BY BUSINESS UNIT
U.S. dollar in millions, REPORTED

 

      1Q15       2Q15       3Q15       4Q15       FY15       1Q16       1Q16 vs. 1Q15  
Net sales                                                        
                                                         
Cardio Pulmonary   $ 107.5     $ 125.9     $ 113.0     $ 130.0     $ 476.4     $ 110.9         3.1 %  
Heart Valves     34.7       36.4       34.2       34.9       140.2       32.5         (6.2 %)  
                                                         
Cardiac Surgery Total     142.2       162.3       147.2       164.9       616.6       143.4         0.9 %  
CRM     70.4       75.6       53.9       60.7       260.5       61.7         (12.3 %)  
Neuromodulation     70.1       78.4       84.3       91.5       324.3       81.4         16.0 %  
                                                         
Other     0.7       0.7       0.8       0.9       3.2       0.4         NM    
                                                         
Total   $ 283.4     $ 317.1     $ 286.1     $ 318.0     $ 1,204.6     $ 287.0         1.2 %  
                                                             

 

___________

The sales results presented are unaudited.  Numbers may not add due to rounding.

LIVANOVA PLC7
QUARTERLY SALES TREND BY REGION
U.S. dollar in millions, CONSTANT CURRENCY

      1Q15       2Q15       3Q15       4Q15       FY15       1Q16       1Q16 vs. 1Q15
Cardio Pulmonary                                                      
US   $ 32.9     $ 43.0     $ 39.8     $ 45.9     $ 161.7     $ 34.5         4.7 %
Europe     33.6       37.1       31.7       35.6       137.9       32.4         (3.7 %)
Rest of World     41.0       45.9       41.5       48.5       176.9       46.6         13.6 %
Total     107.5       125.9       113.0       130.0       476.4       113.4         5.5 %
                                                       
Heart Valve                                                      
US     6.7       6.7       6.1       5.8       25.2       6.5         (3.6 %)
Europe     12.8       13.0       10.3       10.9       46.9       11.7         (8.4 %)
Rest of World     15.2       16.8       17.8       18.2       68.1       15.2         0.1 %
Total     34.7       36.4       34.2       34.9       140.2       33.4         (3.7 %)
                                                       
Cardiac Surgery                                                      
US     39.6       49.6       45.9       51.7       186.9       40.9         3.3 %
Europe     46.3       50.0       41.9       46.5       184.8       44.0         (5.0 %)
Rest of World     56.2       62.7       59.3       66.7       245.0       61.8         10.0 %
Total     142.2       162.3       147.2       164.9       616.6       146.8         3.2 %
                                                       
CRM                                                      
US     4.5       3.9       3.9       3.1       15.5       3.0         (34.4 %)
Europe     51.0       52.3       44.8       50.5       198.6       51.2         0.5 %
Rest of World     14.9       19.4       5.1       7.0       46.4       8.7         (41.5 %)
Total     70.4       75.6       53.9       60.7       260.5       62.9         (10.7 %)
                                                       
Neuromodulation                                                      
US     57.5       63.6       70.9       76.8       268.8       70.2         22.2 %
Europe     8.7       8.9       8.4       9.2       35.2       6.6         (24.5 %)
Rest of World     3.9       6.0       4.9       5.5       20.3       4.8         21.8 %
Total     70.1       78.4       84.3       91.5       324.3       81.6         16.4 %
                                                       
Other                                                      
US     0.0       0.0       0.0       0.0       0.0       0.0          
Europe     0.0       0.0       0.0       0.2       0.3       0.1          
Rest of World     0.7       0.7       0.8       0.7       2.9       0.5         NM  
Total     0.7       0.7       0.8       0.9       3.2       0.5         NM  
                                                       
Total                                                      
US     101.6       117.1       120.8       131.6       471.2       114.1         12.3 %
Europe     106.1       111.2       95.2       106.4       418.8       101.9         (3.9 %)
Rest of World     75.7       88.8       70.2       79.9       314.6       75.8         0.0 %
Total   $ 283.4     $ 317.1     $ 286.1     $ 318.0     $ 1,204.6     $ 291.8     $   3.0 %
                                                           

___________

7 The sales results presented are unaudited.  Numbers may not add due to rounding.

LIVANOVA PLC8
QUARTERLY SALES TREND BY REGION
U.S. dollar in millions, REPORTED

      1Q15       2Q15       3Q15       4Q15       FY15       1Q16       1Q16 vs. 1Q15
Cardio Pulmonary                                                      
US   $ 32.9     $ 43.0     $ 39.8     $ 45.9     $ 161.7     $ 34.5         4.7 %
Europe     33.6       37.1       31.7       35.6       137.9       31.5         (6.3 %)
Rest of World     41.0       45.9       41.5       48.5       176.9       45.0         9.7 %
Total     107.5       125.9       113.0       130.0       476.4       110.9         3.1 %
                                                       
Heart Valve                                                      
US     6.7       6.7       6.1       5.8       25.2       6.5         (3.6 %)
Europe     12.8       13.0       10.3       10.9       46.9       11.4         (10.7 %)
Rest of World     15.2       16.8       17.8       18.2       68.1       14.7         (3.5 %)
Total     34.7       36.4       34.2       34.9       140.2       32.5         (6.2 %)
                                                       
Cardiac Surgery                                                      
US     39.6       49.6       45.9       51.7       186.9       40.9         3.3 %
Europe     46.3       50.0       41.9       46.5       184.8       42.9         (7.5 %)
Rest of World     56.2       62.7       59.3       66.7       245.0       59.7         6.1 %
Total     142.2       162.3       147.2       164.9       616.6       143.4         0.9 %
                                                       
CRM                                                      
US     4.5       3.9       3.9       3.1       15.5       3.0         (34.4 %)
Europe     51.0       52.3       44.8       50.5       198.6       50.0         (1.9 %)
Rest of World     14.9       19.4       5.1       7.0       46.4       8.7         (41.2 %)
Total     70.4       75.6       53.9       60.7       260.5       61.7         (12.3 %)
                                                       
Neuromodulation                                                      
US     57.5       63.6       70.9       76.8       268.8       70.2         22.2 %
Europe     8.7       8.9       8.4       9.2       35.2       6.4         (27.3 %)
Rest of World     3.9       6.0       4.9       5.5       20.3       4.8         21.3 %
Total     70.1       78.4       84.3       91.5       324.3       81.4         16.0 %
                                                       
Other                                                      
US     0.0       0.0       0.0       0.0       0.0       0.0          
Europe     0.0       0.0       0.0       0.2       0.3       0.1          
Rest of World     0.7       0.7       0.8       0.7       2.9       0.4         NM  
Total     0.7       0.7       0.8       0.9       3.2       0.4         NM  
                                                       
Total                                                      
US     101.6       117.1       120.8       131.6       471.2       114.1         12.3 %
Europe     106.1       111.2       95.2       106.4       418.8       99.3         (6.4 %)
Rest of World     75.7       88.8       70.2       79.9       314.6       73.5         (2.9 %)
Total   $ 283.4     $ 317.1     $ 286.1     $ 318.0     $ 1,204.6     $ 287.0     $   1.2 %
                                                           

___________

8 The sales results presented are unaudited.  Numbers may not add due to rounding.

LIVANOVA PLC9
QUARTERLY SALES 
U.S. dollar in millions

    Three Months Ended March 31                
      2016       2015       % Change at
Actual
Currency Rates
      % Change at
Constant
Currency Rates
 
Cardio Pulmonary                                
US   $ 34.5     $ 32.9         4.7 %         4.7 %  
Europe     31.5       33.6         (6.3 %)         (3.7 %)  
Rest of World     45.0       41.0         9.7 %         13.6 %  
Total     110.9       107.5         3.1 %         5.5 %  
                                 
Heart Valve                                
US     6.5       6.7         (3.6 %)         (3.6 %)  
Europe     11.4       12.8         (10.7 %)         (8.4 %)  
Rest of World     14.7       15.2         (3.5 %)         0.1 %  
Total     32.5       34.7         (6.2 %)         (3.7 %)  
                                 
Cardiac Surgery                                
US     40.9       39.6         3.3 %         3.3 %  
Europe     42.9       46.3         (7.5 %)         (5.0 %)  
Rest of World     59.7       56.2         6.1 %         10.0 %  
Total     143.4       142.2         0.9 %         3.2 %  
                                 
CRM                                
US     3.0       4.5         (34.4 %)         (34.4 %)  
Europe     50.0       51.0         (1.9 %)         0.5 %  
Rest of World     8.7       14.9         (41.2 %)         (41.5 %)  
Total     61.7       70.4         (12.3 %)         (10.7 %)  
                                 
Neuromodulation                                
US     70.2       57.5         22.2 %         22.2 %  
Europe     6.4       8.7         (27.3 %)         (24.5 %)  
Rest of World     4.8       3.9         21.3 %         21.8 %  
Total     81.4       70.1         16.0 %         16.4 %  
                                 
Other                                
US     0.0       0.0                      
Europe     0.1       0.0                      
Rest of World     0.4       0.7         NM           NM    
Total     0.4       0.7         NM           NM    
                                 
Total                                
US     114.1       101.6         12.3 %         12.3 %  
Europe     99.3       106.1         (6.4 %)         (3.9 %)  
Rest of World     73.5       75.7         (2.9 %)         0.0 %  
Total   $ 287.0     $ 283.4         1.2 %         3.0 %  
                                         


 

___________

9 The sales results presented are unaudited.  Numbers may not add due to rounding.

LIVANOVA PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF INCOME / (LOSS)
U.S. dollars in millions, except share and per share amounts
Unaudited

      Three Months Ended
March 31, 2016
 
         
Net sales   $ 287.0  
Cost of sales     123.6  
Gross profit     163.4  
         
Operating expenses        
Selling, general and administrative     115.6  
Research and development     31.7  
Merger and integration expense     6.8  
Restructuring expense     28.6  
Amortization of intangible assets     15.9  
Litigation related expenses     1.0  
Total operating expenses     199.5  
Income (loss) from operations     (36.1 )
         
Other income (expense)        
Interest income (expense)     1.0  
Foreign exchange and other     1.8  
Income (loss) before income taxes     (38.9 )
         
Loss from equity method investments     2.7  
Income tax expense (benefit)     (1.3 )
Net (loss) income   $ (40.4 )
         
Earnings (loss) per common share:        
Basic   $ (0.83 )
Diluted   $ (0.83 )
         
Weighted average common shares outstanding (in millions)        
Basic     48.9  
Diluted     48.9  
  Numbers may not add due to rounding.            


 

LIVANOVA PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS10
ADJUSTED FOR NON-GAAP ITEMS11
U.S. dollars in millions, except share and per share amounts
Unaudited

      1Q15       2Q15       3Q15       4Q15       FY1512       1Q16       1Q16 vs. 1Q15  
                                                         
Net sales   $   283.4       $   317.1       $   286.1       $   318.0       $   1,204.6       $   287.0           1.2 %  
Cost of sales       101.7           117.8           103.7           121.2           444.4           101.9           0.1 %  
Gross profit       181.7           199.3           182.5           196.8           760.2           185.1           1.9 %  
                                                         
Operating expenses:                                                        
Selling, general and administrative       108.2           113.0           106.7           117.0           444.9           110.2           1.8 %  
Research and development       36.6           35.6           35.8           35.2           143.2           31.4           (14.2 %)  
Total operating expenses       144.8           148.6           142.5           152.2           588.0           141.5           (2.2 %)  
Income (loss) from operations       36.9           50.7           40.0           44.6           172.2           43.5           17.9 %  
                                                         
Other income (expense)                                                        
Interest expense       1.3           2.2           1.8           1.1           6.3           1.0              
Foreign exchange and other       (0.7 )         1.3           1.8           (1.1         (1.3 )         1.8              
IIncome (loss) before income taxes       36.4           47.2           36.4           44.6           164.6           40.7           11.8 %  
Loss from equity method investments       2.9           3.5           1.1           5.0           12.4           2.7           (7.2 %)  
Income tax expense (benefit)                                               11.5            
Net (loss) income                                           $   26.5            
                                                         
Earnings (loss) per common share                                                        
Basic                                           $   0.54            
Diluted                                           $   0.54            
                                                         
Weighted average common shares outstanding                                                        
Basic                                               48.9            
Diluted                                               49.1            
                                                         
Gross profit as a % of sales       64.1 %         62.8 %         63.8 %         61.9 %         63.1 %         64.5 %          
SG&A as a % of sales       38.2 %         35.6 %         37.3 %         36.8 %         36.9 %         38.4 %          
R&D as a % of sales       12.9 %         11.2 %         12.5 %         11.1 %         11.9 %         10.9 %          
Operating income as a % of sales       13.0 %         16.0 %         14.0 %         14.0 %         14.3 %         15.2 %        


 

___________

10 See the discussion of “Financial Alignment, Combined Sales & Operating Results, Business Unit Structure and Constant Currency” above.

11 Please see “Use of Non-GAAP Financial Measures” above.  Numbers may not add due to rounding.

12 The Selected Non-GAAP Operating Results presented for 2015 include adjustments relating to purchase price accounting, equity compensation expense, merger, integration and restructuring expenses, certain reclassifications, certain losses of foreign exchange hedging arrangements and other one-time expenses, as presented on February 24. 

LIVANOVA PLC AND SUBSIDIARIES
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES13
U.S. dollars in millions, except share and per share amounts
Unaudited

Three Months Ended March 31, 2016     Gross Profit       (Loss) /Income From 
Operations
       Net (Loss) /Income       Diluted EPS  
                                 
GAAP Financial Measures   $ 163.4     $ (36.1 )   $ (40.4 )   $ (0.83 )
Specified Items                                
Merger and integration expense             6.8       5.9       0.12  
Restructuring expense1             28.6       26.8       0.55  
Amortization of intangible assets2             15.9       10.9       0.22  
Litigation related expenses3             1.0       0.9       0.02  
Impact of inventory step-up4     21.3       21.3       14.6       0.30  
Equity compensation     0.4       6.1       5.3       0.11  
Certain tax adjustments5                     2.5       0.05  
Adjusted financial measures   $ 185.1     $ 43.5     $ 26.5     $ 0.54  
  Notes
1 Restructuring expenses, including CRM restructuring announced March 10, 2016.
2 Includes amortization associated with preliminary purchase price accounting.
3 Expenses associated with litigation in respect of heater/cooler matter.
4 Includes the amortization of inventory step-up associated with preliminary purchase price accounting.
5 Relates to the impact of restructuring initiatives.
   

___________

13 Please see "Use of Non-GAAP Financial Measures" above.  Numbers may not add due to rounding.

LIVANOVA PLC AND SUBSIDIARIES 
CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. dollars in millions

      March 31, 2016       December 31, 2015
      (Unaudited)        
ASSETS              
               
Current Assets:              
Cash and cash equivalents   $ 87.5     $ 112.6
Short-term investments     7.0       7.0
Accounts receivable, net     288.5       272.4
Inventories     210.8       212.5
Prepaid taxes     51.4       42.4
Prepaid expenses and other current assets     38.6       26.6
Total Current Assets     683.7       673.4
Property, plant and equipment, net     253.8       244.6
Goodwill     752.3       745.4
Intangible assets, net     674.7       658.9
Investments     77.7       77.5
Deferred tax assets, net     157.8       153.5
Other assets     5.5       5.4
Total Assets   $ 2,605.5     $ 2,558.7
               
LIABILITIES AND STOCKHOLDERS’ EQUITY              
               
Current Liabilities:              
Current debt obligations   $ 75.5     $ 82.5
Accounts payable     118.9       109.6
Accrued liabilities     95.1       80.5
Income taxes payable     27.0       26.7
Accrued employee compensation and related benefits liability     65.1       59.8
Total Current Liabilities     381.5       359.1
Long-term debt obligations     96.1       91.8
Deferred income taxes liability     250.5       235.5
Long-term employee compensation and related benefits liability     32.5       31.1
Other long-term liabilities     31.8       29.7
Total Liabilities     792.5       747.3
Total Stockholders’ Equity     1,813.0       1,811.5
Total Liabilities and Stockholders’ Equity   $ 2,605.5     $ 2,558.7
 


 

Numbers may not add due to rounding.

LIVANOVA PLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS 
U.S. dollars in millions
Unaudited

      Three Months 
Ended

March 31, 2016
 
         
Cash Flows From Operating Activities        
Net income (loss)   $ (40.4 )
Non-cash items included in net income (loss):        
Depreciation and amortization     23.6  
Stock-based compensation     6.1  
Deferred income tax expense     1.3  
Impairment of intangible assets      
Loss on disposal of assets     0.1  
Loss from equity method investments     2.7  
Unrealized (gain) loss in foreign currency transactions     (0.7 )
Restructuring reserves, increase     22.0  
Bad debt allowances and other reserves, net increase     3.3  
Changes in operating assets and liabilities        
Accounts receivable     (8.4 )
Inventories     10.8  
Other current and non-current assets     (16.0 )
Current and non-current liabilities     5.2  
Net cash provided by (used in) operating activities     9.6  
Cash Flow From Investing Activities        
Purchase of short-term investments     (7.0 )
Maturities of short-term investments     7.0  
Purchase of property, plant and equipment and other     (8.1 )
Intangible assets purchases     (0.8 )
Net cash used in investing activities     (8.9 )
Cash Flows From Financing Activities:        
Short-term borrowing     14.1  
Short-term repayments     (24.4 )
Repayment of long-term debt obligations     (0.6 )
Purchase of treasury stock      
Proceeds from exercise of options for common stock     2.5  
Cash settlement of compensation-based stock units      
Realized excess tax benefits - stock-based compensation     0.7  
Other financial assets and liabilities     (19.4 )
Net cash used in financing activities     (27.1 )
Effect of exchange rate changes on cash and cash equivalents     1.3  
Net increase (decrease) in cash and cash equivalents     (25.1 )
Cash and cash equivalents at beginning of period     112.6  
Cash and cash equivalents at end of period   $ 87.5  
         

Numbers may not add due to rounding.

LIVANOVA  PLC AND SUBSIDIARIES 
2016 PROJECTIONS

Net sales growth (on a constant currency basis):  
Worldwide 3% - 5%
Cardiac Surgery 3% - 5%
Neuromodulation 9% - 11%
CRM 1% - 2%
Adjusted gross profit (as a percentage of net sales) 64% - 65%
Adjusted R&D expenses as a percentage of sales 11% - 12%
Adjusted income from operations $205 - $230 million
Finance cost and losses on minority investments ~$20 million - $25 million
Adjusted effective tax rate 24% - 26%
Adjusted earnings per share (excluding equity compensation expense) $2.95 to $3.15
Number of fully diluted shares ~50 million
Adjusted EBITDA $235 - $260 million
   
   
* Adjusted financial measures are considered non-GAAP.
   
* The Company expects substantial one-time expenses in its reported financial statements during 2016 related to the recent merger, including for purchase price accounting, amortization, merger, integration and restructuring expenses, and other one-time payments.
   
* Adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP diluted earnings per share exclude expenses relating to purchase price accounting, amortization, merger, integration and restructuring expenses, other one-time payments, tax adjustments and equity compensation expense.
   
* Average Euro/Dollar exchange rate of $1.10.




 

 

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Promethean Opens New Global Headquarters in Seattle18.8.2017 18:38Pressemelding

Seattle, Wash., Aug. 18, 2017 (GLOBE NEWSWIRE) -- PrometheanTM, a global education technology company, announced today the opening of its new global headquarters in Seattle, Wash. Promethean's office in Atlanta, Ga. will continue to serve as the hub for the Americas markets, and the Blackburn, U.K. office will continue to carry on as the hub for the EMEA markets and parts of Asia.  Promethean is one of the leading brands in the international education technology market with more than 20 years of experience in the K-12 classroom. Its solutions are in more than 50,000 schools and institutions in 154 countries. "As traditional pedagogy continues to move towards immersive learning, it's important for Promethean to lead innovation in education with the latest technology," said Vin Riera, CEO of Promethean. "Seattle is a global technology hub, and establishing Promethean's global headquarters there increases opportunities for new business models, concepts

Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00Pressemelding

Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressemelding

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressemelding

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressemelding

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressemelding

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom